Michaela Johnson
Nurse Practitioner · Waterloo, IANPI 1407312549
Payments from drug & device makers
Across 600 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- AstraZeneca$1K
- AbbVie$963
- Lilly USA, LLC$900
- Boehringer Ingelheim$885
- Novartis$419
- plus $4K from 29 others
What the payments were for
- Food & beverage$9,22599%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 88 | $1,304 |
| AstraZeneca | 59 | $1,020 |
| AbbVie | 66 | $963 |
| Lilly USA, LLC | 67 | $900 |
| Boehringer Ingelheim | 58 | $885 |
| Novartis | 28 | $419 |
| Amgen | 22 | $324 |
| E.r. Squibb & Sons, L.L.C. | 23 | $298 |
| Novo Nordisk | 17 | $295 |
| GSK | 19 | $262 |
| Exact Sciences | 14 | $238 |
| Merck | 18 | $222 |
| Astellas Pharma US Inc | 10 | $210 |
| Johnson & Johnson(2 entities) | 13 | $205 |
| Otsuka America Pharmaceutical, Inc. | 11 | $193 |
| Sanofi-aventis U.S. LLC | 10 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $168 |
| Phathom Pharmaceuticals, Inc. | 7 | $160 |
| Xeris Pharmaceuticals, Inc. | 8 | $139 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $130 |
| Bayer | 7 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $91 |
| Abbott | 3 | $89 |
| Kowa Pharmaceuticals America, Inc. | 5 | $73 |
| Idorsia Pharmaceuticals US Inc | 5 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $62 |
| Biohaven Pharmaceuticals, Inc. | 2 | $47 |
| Mylan Specialty L.p. | 3 | $45 |
| Amarin Pharma, Inc. | 3 | $44 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Radius Health, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
How this compares
$9,287 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 39 | $41,961 |
| JardianceEmpagliflozin | 39 | $29,523 |
| WegovySemaglutide | 12 | $16,362 |
| EliquisApixaban | 16 | $16,064 |
| FarxigaDapagliflozin Propanediol | 25 | $15,716 |
| TrulicityDulaglutide | 11 | $10,463 |
| XareltoRivaroxaban | 12 | $7,169 |
| MyrbetriqMirabegron | 14 | $6,576 |
| Novolog FlexpenInsulin Aspart | 18 | $2,906 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,138 |
| Levothyroxine Sodium | 100 | $1,126 |
| Rosuvastatin Calcium | 75 | $827 |
| Omeprazole | 78 | $778 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $723 |
| Doxycycline Hyclate | 12 | $713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $900 | $52,42450 claims |
| Boehringer IngelheimJardiance | $885 | $29,52339 claims |
| Novo NordiskWegovy | $295 | $16,36212 claims |
| PfizerEliquis | $1,304 | $16,06416 claims |
| AstraZenecaFarxiga | $1,020 | $15,71625 claims |
| Johnson & JohnsonXarelto | $205 | $7,16912 claims |
| Astellas Pharma US IncMyrbetriq | $210 | $6,57614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Other nurse practitioner in Waterloo
- Jonathon HenningsWaterloo$11K
- Megan O'NealWaterloo$4K
- Crystal SchraderWaterloo$4K
- Irmela SalihovicWaterloo$4K
- Stephanie SmithWaterloo$3K
- Nicole MorganDes Moines$106K
- Julie CoffeyIowa City$31K
- Mary JohnsonDavenport$30K
- Megan Hart FernandezCedar Rapids$19K
- Carla HuberCedar Rapids$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.